Europe Cholesterol Testing Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Europe Cholesterol Testing Market Size

• The Europe cholesterol testing market size was valued at USD 5.57 billion in 2025 and is expected to reach USD 8.94 billion by 2033, at a CAGR of 6.10% during the forecast period
• The market growth is largely fueled by increasing awareness of cardiovascular health, rising prevalence of cholesterol-related disorders, and the widespread adoption of preventive healthcare and routine diagnostic screening across Europe
• Furthermore, technological advancements in rapid, accurate, and user-friendly cholesterol testing devices, along with growing consumer preference for point-of-care testing and home-based monitoring solutions, are driving the demand. These converging factors are accelerating the uptake of cholesterol testing solutions, thereby significantly boosting the industry’s growth

Europe Cholesterol Testing Market Analysis

• Cholesterol testing, including assays for total cholesterol, LDL, HDL, and triglycerides, is increasingly vital in preventive healthcare and cardiovascular risk management across both clinical and home-based settings due to its ability to enable early detection, personalized intervention, and routine health monitoring
• The escalating demand for cholesterol testing is primarily fueled by growing awareness of cardiovascular diseases, increasing prevalence of hypercholesterolemia, and the rising adoption of preventive healthcare programs across Europe
• Germany dominated the Europe cholesterol testing market with the largest revenue share of 25.8% in 2025, characterized by high health awareness, advanced healthcare infrastructure, and strong presence of key diagnostic companies, with substantial adoption of advanced testing devices in clinics, hospitals, and home-based monitoring, driven by innovations in point-of-care and rapid testing technologies
• Italy is expected to be the fastest growing country in the Europe cholesterol testing market during the forecast period due to increasing healthcare accessibility, rising disposable incomes, and government initiatives promoting preventive cardiovascular healthcare
• The Test Kits segment dominated the cholesterol testing market with a market share of 42.6% in 2025, driven by their convenience, ease of use in clinical and home settings, rapid results, and suitability for integration into routine monitoring programs

Report Scope and Europe Cholesterol Testing Market Segmentation

Europe Cholesterol Testing Market Trends

Advancements in Point-of-Care and Home-Based Testing

• A significant and accelerating trend in the Europe cholesterol testing market is the development and adoption of advanced point-of-care (POC) and home-based cholesterol testing kits, enabling faster, more accurate, and convenient monitoring of blood lipid levels
  • For instance, the CardioCheck Plus system allows patients to perform cholesterol testing at home with lab-accurate results, while Roche Accutrend Plus provides portable POC testing for clinics and community health centers
• Integration of digital health platforms and mobile applications with cholesterol testing devices enables automated tracking of results, alerts for abnormal readings, and remote monitoring by healthcare professionals. For instance, Alere Cholestech LDX integrates with mobile apps to provide data visualization and trend tracking
• The seamless integration of cholesterol testing with broader preventive health and digital health platforms facilitates personalized healthcare management, allowing users to combine cholesterol data with other vital metrics such as blood glucose and blood pressure for a comprehensive health overview
• This trend towards faster, more accessible, and patient-centric testing is reshaping expectations for cardiovascular health management. Consequently, companies such as Siemens Healthineers are developing compact, AI-enabled devices capable of rapid lipid profiling and home monitoring
• The demand for innovative cholesterol testing solutions that offer convenience, accuracy, and connectivity is growing rapidly across both clinical and home-based healthcare settings, as patients and practitioners increasingly prioritize proactive disease management
• Remote telehealth consultations linked with cholesterol testing results are becoming more common, allowing healthcare providers to adjust treatments and lifestyle recommendations without requiring in-person visits

Europe Cholesterol Testing Market Dynamics

Driver

Rising Prevalence of Cardiovascular Disorders and Preventive Healthcare Awareness

• The increasing incidence of hypercholesterolemia and cardiovascular diseases, coupled with growing awareness of preventive healthcare, is a significant driver for the heightened demand for cholesterol testing in Europe
  • For instance, in March 2025, Roche Diagnostics launched an outreach program promoting routine cholesterol screening in primary care centers, aiming to identify at-risk individuals early
• As patients become more conscious of heart disease risks and seek proactive monitoring, cholesterol testing kits and POC devices offer timely and actionable insights to guide interventions and lifestyle modifications
• Furthermore, the expansion of healthcare initiatives promoting preventive cardiovascular screening is increasing adoption in clinics, pharmacies, and home-based healthcare programs
• The convenience of rapid results, ease of sample collection, and the ability to monitor cholesterol trends over time through digital platforms are key factors propelling adoption in both clinical and home settings
• Increasing partnerships between diagnostic companies and pharmacies to offer cholesterol testing services is expanding market reach and accessibility for consumers
• Growing government and private sector campaigns emphasizing cardiovascular risk awareness and early screening are further boosting the adoption of cholesterol testing solutions across Europe

Restraint/Challenge

Accuracy Concerns and Regulatory Compliance Hurdles

• Concerns surrounding the accuracy and standardization of home-based cholesterol testing, along with stringent regulatory compliance requirements, pose significant challenges to broader market penetration
  • For instance, discrepancies between POC test results and laboratory-based cholesterol measurements have caused some healthcare professionals to remain cautious about fully endorsing home kits
• Addressing these accuracy concerns through validated testing protocols, regulatory approvals, and user training is crucial for building confidence among patients and clinicians. Companies such as Abbott and CardioChek emphasize lab-correlated accuracy and compliance in their marketing
• Additionally, relatively high costs of advanced cholesterol testing kits compared to traditional lab testing can be a barrier for price-sensitive users, particularly in countries with limited reimbursement programs. While basic kits have become more affordable, premium devices with digital connectivity often carry higher prices
• Overcoming these challenges through certified accuracy, consumer education, and development of cost-effective yet reliable testing solutions will be vital for sustained market growth
• Inconsistent healthcare policies and reimbursement structures across different European countries can slow adoption and limit market penetration in certain regions
• Potential lack of user awareness or proper training in home-based testing procedures may result in improper usage or misinterpretation of results, creating a barrier to adoption

Europe Cholesterol Testing Market Scope

The market is segmented on the basis of product type, test type, test method, prescription mode, and end-users.

• By Product Type

On the basis of product type, the Europe cholesterol testing market is segmented into test kits and testing strips. The Test Kits segment dominated the market with the largest revenue share of 42.6% in 2025, driven by their convenience, accuracy, and ability to provide rapid results in both clinical and home settings. Test kits are widely adopted in hospitals, clinics, and diagnostic centers due to their ease of use, minimal training requirements, and compatibility with digital health platforms. Homecare users prefer test kits for regular monitoring of cholesterol levels without the need for laboratory visits. The strong presence of established diagnostic companies offering validated kits further supports this dominance. Moreover, test kits often come with integrated software or apps for result tracking, making them attractive to tech-savvy consumers.

The Testing Strips segment is expected to witness the fastest growth during the forecast period due to its affordability and ease of integration with portable and handheld cholesterol testing devices. Strips allow for quick point-of-care testing, making them suitable for homecare, pharmacies, and community health programs. Rising health awareness and the increasing prevalence of hypercholesterolemia are encouraging users to adopt strip-based monitoring. Their compact design and minimal storage requirements make them ideal for frequent use and travel. Furthermore, innovation in strip accuracy and compatibility with smartphone-connected devices is fueling adoption. Healthcare providers are promoting testing strips as part of preventive health campaigns, contributing to their rapid market growth.

• By Test Type

On the basis of test type, the Europe cholesterol testing market is segmented into Total Cholesterol Test, High-Density Lipoprotein (HDL) Cholesterol, and Low-Density Lipoprotein (LDL) Cholesterol. The Total Cholesterol Test segment dominated the market in 2025 due to its widespread use as a primary indicator of cardiovascular health risk. Clinicians often recommend total cholesterol testing during routine check-ups and preventive health screenings. Laboratories, clinics, and hospitals prefer total cholesterol testing kits because they provide a quick overview of lipid profiles. The segment benefits from strong awareness campaigns emphasizing the importance of monitoring total cholesterol. Integration with digital reporting systems and telehealth platforms further drives its adoption. Patients undergoing regular health monitoring rely heavily on total cholesterol tests to evaluate overall cardiovascular risk.

The LDL Cholesterol Test segment is expected to witness the fastest growth during the forecast period owing to increased awareness of “bad cholesterol” and its direct association with heart disease. LDL tests are increasingly recommended for high-risk populations, including diabetic and hypertensive patients. Growing preventive healthcare initiatives by governments and private organizations in Europe are promoting LDL testing. Technological advancements have made LDL testing kits more accurate, compact, and accessible for home and clinical use. Increasing adoption in pharmacies and ambulatory centers also contributes to faster growth. Telemedicine integration allows LDL results to be shared with healthcare providers for real-time consultation, further boosting market adoption.

• By Test Method

On the basis of test method, the Europe cholesterol testing market is segmented into non-invasive and invasive testing. The Non-Invasive segment dominated the market in 2025 due to growing consumer preference for pain-free, easy-to-use diagnostic solutions. Non-invasive testing, such as finger-prick or saliva-based tests, provides immediate results with minimal discomfort, increasing compliance among patients. Hospitals, clinics, and homecare users increasingly favor non-invasive methods for regular monitoring. The segment benefits from integration with digital devices and health apps for tracking and reporting results. Non-invasive tests also reduce the need for specialized training and laboratory infrastructure, facilitating broader adoption. Awareness campaigns highlighting the convenience and safety of non-invasive methods further support market dominance.

The Invasive segment is expected to witness the fastest growth during the forecast period due to its accuracy and applicability in specialized clinical settings. Invasive methods, such as venous blood sampling, remain the standard in hospitals and diagnostic laboratories for detailed lipid profiling. Rising cardiovascular disease prevalence and the need for precise diagnosis in high-risk patients drive adoption. Invasive testing is preferred when confirmatory results are required for medical interventions. Technological improvements in sample processing and faster laboratory turnaround times support growth. Growing collaboration between hospitals and diagnostic centers ensures wider availability of invasive testing solutions across Europe.

• By Prescription Mode

On the basis of prescription mode, the Europe cholesterol testing market is segmented into Over-the-Counter (OTC) and Prescription-Based testing. The Over-the-Counter segment dominated the market with a large revenue share in 2025 due to increasing consumer preference for self-monitoring of cholesterol at home. OTC tests allow patients to track their cholesterol conveniently without visiting a doctor, supporting preventive healthcare adoption. The segment benefits from rising health awareness campaigns and availability in pharmacies and online platforms. OTC tests are often integrated with digital apps, allowing automated result tracking and alerts. High accessibility, affordability, and ease of use contribute to strong adoption. Patients managing lifestyle changes or medication adherence frequently rely on OTC cholesterol tests for real-time monitoring.

The Prescription-Based segment is expected to witness the fastest growth during the forecast period due to increasing chronic disease management programs and regulatory encouragement for clinical monitoring. Prescription tests are widely used in hospitals, clinics, and diagnostic centers where professional supervision ensures accurate results and interpretation. Chronic disease patients, including diabetics and hypertensive individuals, rely on prescription-based testing for ongoing monitoring. Growing telemedicine adoption supports remote sharing of prescription test results. Prescription-based tests are often coupled with advanced laboratory analysis and quality assurance, increasing clinical confidence. Expansion of preventive health initiatives by governments and healthcare providers is further boosting segment growth.

• By End-Users

On the basis of end-users, the Europe cholesterol testing market is segmented into clinics, hospitals, ambulatory centers, homecare, and diagnostic centers. The Hospitals segment dominated the market in 2025 with the largest revenue share due to the high patient volume, advanced infrastructure, and availability of specialized laboratories for cholesterol testing. Hospitals offer both inpatient and outpatient testing, enabling comprehensive cardiovascular risk management programs. Integration with hospital information systems and electronic medical records enhances operational efficiency. Patients prefer hospital-based testing for accuracy and professional supervision. Strong partnerships between hospitals and diagnostic companies facilitate adoption of advanced testing devices. Hospitals also serve as centers for preventive health campaigns, further boosting market share.

The Homecare segment is expected to witness the fastest growth during the forecast period due to the rising adoption of self-monitoring and point-of-care testing solutions. Homecare users increasingly prefer test kits and strips for convenience, especially during routine monitoring or lifestyle management programs. Integration with digital health platforms allows real-time sharing of results with physicians. The growing popularity of telehealth and remote monitoring initiatives in Europe supports the adoption of home-based testing. Rising awareness about cardiovascular diseases and preventive healthcare is encouraging patients to monitor cholesterol independently. Homecare also benefits from affordability, accessibility, and the convenience of avoiding clinic visits, driving rapid growth.

Europe Cholesterol Testing Market Regional Analysis

• Germany dominated the Europe cholesterol testing market with the largest revenue share of 25.8% in 2025, characterized by high health awareness, advanced healthcare infrastructure, and strong presence of key diagnostic companies
• Consumers and patients in these countries highly value the convenience, rapid results, and accuracy offered by modern cholesterol testing devices, including point-of-care kits and home-based monitoring solutions
• This widespread adoption is further supported by strong government health initiatives, well-established diagnostic networks, and increasing integration of cholesterol testing with digital health platforms, establishing these countries as leaders in preventive cardiovascular care across Europe

The U.K. Cholesterol Testing Market Insight

The U.K. cholesterol testing market captured a significant revenue share in 2025, driven by growing awareness of cardiovascular health and preventive healthcare programs. Patients are increasingly prioritizing routine lipid profiling through both clinic-based and home-based testing kits. The rising adoption of point-of-care devices and integration with digital health platforms further propels the market. Moreover, government initiatives promoting early detection of heart disease and well-established healthcare infrastructure are contributing to the market’s expansion. The convenience, speed, and accuracy offered by modern testing devices continue to drive adoption among both patients and healthcare providers.

Germany Cholesterol Testing Market Insight

The Germany cholesterol testing market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing prevalence of hypercholesterolemia and rising demand for preventive healthcare. Germany’s advanced healthcare system, widespread health awareness, and emphasis on technological innovation support the adoption of both invasive and non-invasive testing solutions. Hospitals, clinics, and homecare users increasingly rely on validated test kits and point-of-care devices. Integration with digital health platforms and mobile applications is enhancing patient monitoring and engagement. Furthermore, preventive screening campaigns and insurance coverage for routine testing strengthen market growth.

France Cholesterol Testing Market Insight

The France cholesterol testing market is projected to grow steadily throughout the forecast period due to rising cardiovascular disease awareness and proactive health monitoring programs. French consumers are adopting home-based and point-of-care cholesterol testing kits to manage their lipid profiles conveniently. Healthcare providers are promoting early screening, especially among high-risk populations. Integration of testing devices with telehealth platforms allows remote sharing of results with physicians, boosting adoption. Government initiatives supporting preventive care and a robust diagnostic network also contribute to market growth. The convenience and reliability of modern cholesterol testing solutions continue to drive market expansion in both clinical and home settings.

Italy Cholesterol Testing Market Insight

The Italy cholesterol testing market is expected to witness the fastest growth during the forecast period, driven by increasing awareness of heart disease and growing preventive healthcare initiatives. Rising adoption of home-based testing and point-of-care devices enables convenient and timely cholesterol monitoring. Italian consumers are drawn to non-invasive and rapid testing options, while clinics and ambulatory centers adopt advanced kits for routine screenings. Integration with mobile health applications enhances patient engagement and monitoring. Government campaigns promoting cardiovascular health further support market expansion. Rising disposable incomes and urbanization are also contributing to increased adoption of cholesterol testing solutions.

Europe Cholesterol Testing Market Share

The Europe Cholesterol Testing industry is primarily led by well-established companies, including:

• Thermo Fisher Scientific Inc. (U.S.)
• Abbott (U.S.)
• Eurofins Scientific SE (Luxembourg)
• Randox Laboratories Ltd. (U.K.)
• Labcorp (U.S.)
• SYNLAB AG (Germany)
• Quest Diagnostics Incorporated (U.S.)
• Fresenius SE & Co. KGaA (Germany)
• Novartis AG (Switzerland)
• Bio Rad Laboratories, Inc. (U.S.)
• Beckman Coulter, Inc. (U.S.)
• DiaSorin S.p.A. (Italy)
• PerkinElmer, Inc. (U.S.)
• Ortho Clinical Diagnostics (U.S.)
• BioReference Health, LLC (U.S.)
• Cell Biolabs, Inc. (U.S.)
• ACON Laboratories, Inc. (U.S.)
• Diazyme Laboratories, Inc. (U.S.)
• EKF Diagnostics Holdings plc (U.K.)

What are the Recent Developments in Europe Cholesterol Testing Market?

• In February 2026, an interim evaluation report from Barts Health and UCLPartners revealed that one in five people receiving rapid cholesterol tests in pharmacies were found to be at high risk of heart attack or stroke, highlighting how community pharmacy testing can play a significant role in early cardiovascular disease prevention, especially in underserved populations
• In January 2026, free rapid cholesterol tests pioneered by Barts Health NHS Trust were expanded to 70 pharmacies across east London, enabling fast, seven‑minute screening to estimate cardiovascular risk and connect patients to lifestyle advice or treatment directly at community locations. The programme has already tested over 1,000 people and identified many at high risk of heart attack or stroke, showcasing the potential of decentralized cholesterol screening in community settings
• In August 2025, new rapid pharmacy‑based cholesterol testing pilots were rolled out across East London under an NHS initiative, offering a seven‑minute point‑of‑care lipid test and risk estimate for heart disease, and reinforcing the role of community pharmacy in preventive cardiovascular care
• In June 2025, Poland introduced a comprehensive preventive health programme (“My Health”) that expanded universal lipid screening, including cholesterol checks, into primary care assessments for adults, significantly broadening access to cholesterol testing and follow‑up care as part of national preventive health initiatives
• In September 2024, the FH Europe Foundation’s FH Awareness Day campaign spotlighted the critical need for increased awareness and early diagnosis of familial hypercholesterolaemia across Europe, advocating early screening and personalised prevention strategies to tackle genetic high‑cholesterol risks

SKU-17723